Source:http://linkedlifedata.com/resource/pubmed/id/12946444
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10-11
|
pubmed:dateCreated |
2003-8-29
|
pubmed:abstractText |
Cynomolgus monkeys (Macaca fascicularis) are widely used animal models in biomedical research and have been used to study new therapeutics aimed at B-cell depletion. We have recently identified two different B-cell subsets in cynomolgus monkey, with the CD20lowCD40highCD21+ subset being phenotypically closer to human B cells and having a similar responsivness to anti-CD20 mAb, rituximab, in in vitro depletion assays. Here, we show that similar to in vitro findings CD20highCD40lowCD21- and CD20lowCD40highCD21+ cynomolgus monkey B cells differ significantly in their in vivo susceptibility to rituximab, as the low dose of 0.05 mg/kg of rituximab resulted in more than 70% depletion of the former B-cell subset and virtually no depletion of the latter B-cell subset. Our data suggest that for the B-cell-targeting anti-CD20 therapeutics, depletion of CD20lowCD40highCD21+ subset rather than depletion of all cynomolgus monkey B cells is more relevant to dose-efficacy projections for humans. In addition, we show that differential cell surface expression of CD80/CD86 costimulatory molecules on the two different cynomolgus monkey B-cell subsets is similar to that identified in rhesus monkeys, suggesting that our in vivo study may be relevant to other monkey models.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD20,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD40,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Complement 3d,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1567-5769
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
3
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1477-81
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:12946444-Animals,
pubmed-meshheading:12946444-Antibodies, Monoclonal,
pubmed-meshheading:12946444-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:12946444-Antigens, CD20,
pubmed-meshheading:12946444-Antigens, CD40,
pubmed-meshheading:12946444-Antineoplastic Agents,
pubmed-meshheading:12946444-B-Lymphocyte Subsets,
pubmed-meshheading:12946444-B-Lymphocytes,
pubmed-meshheading:12946444-Lymphocyte Depletion,
pubmed-meshheading:12946444-Macaca fascicularis,
pubmed-meshheading:12946444-Male,
pubmed-meshheading:12946444-Receptors, Complement 3d
|
pubmed:year |
2003
|
pubmed:articleTitle |
Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys.
|
pubmed:affiliation |
Bioanalytical Research and Development Department, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. yulia@gene.com
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|